LRRC8A and cancer: By identifying specific ligands for LRRC8A and conjugating chemotherapy drugs with these LRRC8A-specific ligands, the drugs can be primarily released in cancer cells with high VRAC activity but have minimal impact on normal cells with low VRAC activity, thereby reducing the side effects of chemotherapy.